{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:27:40Z","timestamp":1778840860114,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00277-010-1039-5","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T08:26:40Z","timestamp":1281342400000},"page":"47-52","source":"Crossref","is-referenced-by-count":36,"title":["Characteristics of BCR\u2013ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"90","author":[{"given":"YaZhen","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShanShan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinLan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LingDi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YueYun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YanRong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoJun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"key":"1039_CR2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"S O\u2019Brien","year":"2003","unstructured":"O\u2019Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"1039_CR3","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S et al (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17:2401\u20132409","journal-title":"Leukemia"},{"key":"1039_CR4","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, Muller P, Kreil S et al (2005) Response and resistance in 300 patients with BCR\u2013ABL positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659\u20131669","journal-title":"Cancer"},{"key":"1039_CR5","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"1039_CR6","first-page":"1213","volume":"88","author":"A Sureda","year":"2003","unstructured":"Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA et al (2003) Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 88:1213\u20131220","journal-title":"Haematologica"},{"key":"1039_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al (2002) Multiple BCR\u2013ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"1039_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"1039_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","volume":"249","author":"JV Melo","year":"2007","unstructured":"Melo JV, Chuah C (2007) Resistance to imatinib in chronic myeloid leukaemia. Cancer Lett 249:121\u2013132","journal-title":"Cancer Lett"},{"key":"1039_CR10","doi-asserted-by":"crossref","unstructured":"Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 376\u2013383","DOI":"10.1182\/asheducation-2007.1.376"},{"key":"1039_CR11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","volume":"27","author":"SH Kim","year":"2009","unstructured":"Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J et al (2009) Analysis of Bcr\u2013Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 27:190\u2013197","journal-title":"Hematol Oncol"},{"key":"1039_CR12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"J Apperley","year":"2007","unstructured":"Apperley J (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"key":"1039_CR13","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of abl kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"key":"1039_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-008-0548-y","volume":"88","author":"Y Qin","year":"2009","unstructured":"Qin Y, Jiang B, Jiang Q, Jiang H, Li J, Zhang Y et al (2009) Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol 88:37\u201341","journal-title":"Ann Hematol"},{"key":"1039_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"T Ernst","year":"2006","unstructured":"Ernst T, Erben P, M\u00fcller MC, Paschka P, Schenk T, Hoffmann J et al (2006) Dynamics of BCR\u2013ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93:186\u2013192","journal-title":"Haematologica"},{"key":"1039_CR16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190\u20132196","journal-title":"Leukemia"},{"key":"1039_CR17","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","volume":"104","author":"S Branford","year":"2004","unstructured":"Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR\u2013ABL kinase domain mutations. Blood 104:2926\u20132932","journal-title":"Blood"},{"key":"1039_CR18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI571\/imatinib resistance revealed by mutagenesis of BCR\u2013ABL. Cell 112:831\u2013843","journal-title":"Cell"},{"key":"1039_CR19","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"1039_CR20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-03-011668","volume":"108","author":"N Sorel","year":"2006","unstructured":"Sorel N, Roy L, Martineau G, Guilhot F, Turhan AG, Chomel JC (2006) Sequential emergence of ABL-kinase mutations with loss of unmutated BCR\u2013ABL allele during targeted therapies of CML. Blood 108:1782\u20131783","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-1039-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1039-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:14Z","timestamp":1559037014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-1039-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-1039-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}